<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049660</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-10001-160010</org_study_id>
    <secondary_id>EORTC-10001</secondary_id>
    <secondary_id>EORTC-16001O</secondary_id>
    <secondary_id>IDBBC-EORTC-10001</secondary_id>
    <nct_id>NCT00049660</nct_id>
  </id_info>
  <brief_title>Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized Phase II-III Trial Evaluating the Efficacy of Capecitabine and Vinorelbine in Anthracycline and Taxane Pre-Treated Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. It is not yet known if capecitabine is more effective than&#xD;
      vinorelbine in treating metastatic breast cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II/III trial to compare the effectiveness of capecitabine with that&#xD;
      of vinorelbine in treating women who have metastatic breast cancer that has been previously&#xD;
      treated with chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Phase II Study:&#xD;
&#xD;
        -  Compare the response rate in women with previously treated metastatic breast cancer&#xD;
           treated with capecitabine vs vinorelbine.&#xD;
&#xD;
        -  Compare the duration of response in patients treated with these drugs.&#xD;
&#xD;
      Phase III Study:&#xD;
&#xD;
        -  Compare overall and progression-free survival in patients treated with these drugs.&#xD;
&#xD;
        -  Compare time to treatment failure in patients treated with these drugs.&#xD;
&#xD;
        -  Compare overall safety of these drugs in these patients.&#xD;
&#xD;
        -  Compare quality of life and clinical benefit response in patients treated with these&#xD;
           drugs.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center and taxane resistance (refractory vs resistant vs sensitive).&#xD;
&#xD;
        -  Phase II: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive vinorelbine IV on days 1 and 8. Courses repeat every 21&#xD;
                days.&#xD;
&#xD;
             -  Arm II: Patients receive oral capecitabine twice daily on days 1-14. Courses repeat&#xD;
                every 21 days.&#xD;
&#xD;
      In both arms, treatment continues in the absence of progression or unacceptable toxicity.&#xD;
&#xD;
      If sufficient response rate is determined in phase II, the phase III study is initiated.&#xD;
&#xD;
        -  Phase III: Patients are randomized and receive treatment as in phase II. Quality of life&#xD;
           is assessed prior to randomization, at weeks 3, 6, 9, 18, 24, and 30, and then every 12&#xD;
           weeks until disease progression.&#xD;
&#xD;
      Clinical benefit response is assessed daily while patient is on study.&#xD;
&#xD;
      Patients are followed every 6 weeks until disease progression and then every 12 weeks&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 72 patients (36 per treatment arm) will be accrued for phase II&#xD;
      of this study and a total of 406-452 patients (203-226 per treatment arm) will be accrued for&#xD;
      phase III of this study within 18.5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">47</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Prior treatment with taxanes in the metastatic, adjuvant, or neoadjuvant setting&#xD;
&#xD;
               -  Taxane-resistant disease allowed regardless of duration of prior therapy NOTE:&#xD;
                  Resistant disease defined as progression during or within 12 weeks after taxane&#xD;
                  therapy for metastatic disease or a disease-free interval of less than 12 months&#xD;
                  after neoadjuvant or adjuvant therapy with a taxane&#xD;
&#xD;
               -  Taxane-sensitive disease allowed if at least 4 prior courses were received NOTE:&#xD;
                  Sensitive disease defined as progression occurring more than 12 weeks after&#xD;
                  taxane therapy for metastatic disease or more than 12 months after neoadjuvant or&#xD;
                  adjuvant therapy with a taxane&#xD;
&#xD;
          -  Prior treatment with anthracyclines for metastatic disease or as adjuvant treatment OR&#xD;
             medical contraindication to treatment with anthracyclines&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion (phase II study)&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic ventricular arrhythmias&#xD;
&#xD;
          -  No clinically significant congestive heart failure&#xD;
&#xD;
          -  No clinical or ECG evidence of myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No significant coronary artery disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior malignancy within the past 5 years except contralateral breast cancer,&#xD;
             nonmelanoma skin cancer, and adequately treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No known or prior sensitivity to fluoropyrimidines, including fluorouracil&#xD;
&#xD;
          -  No pre-existing grade 2 or greater neurotoxicity&#xD;
&#xD;
          -  No known malabsorption or upper gastrointestinal abnormalities that would affect&#xD;
             absorption of study drug&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior chemotherapy lines for metastatic disease&#xD;
&#xD;
          -  No prior capecitabine, vinca alkaloids, or continuous fluorouracil&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Bisphosphonate therapy for treatment and prevention of bony metastases allowed if&#xD;
             initiated prior to study&#xD;
&#xD;
          -  No other concurrent investigational treatment&#xD;
&#xD;
          -  No concurrent brivudine with capecitabine&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine J. Piccart-Gebhart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Twelves, MD, BMedSci, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Network Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg - Klinikum Sued</name>
      <address>
        <city>Nurberg</city>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology - Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008 Apr;17(2):180-5. Epub 2007 Oct 31.</citation>
    <PMID>17976988</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

